Dalton Smart

Dalton E.
Smart has held executive roles including Chief Executive Officer, President, Director, and Vice President-Tax at multiple pharmaceutical and biotechnology companies such as Harpoon Therapeutics, Calporta Therapeutics, Prometheus Biosciences, Imago BioSciences, Caraway Therapeutics, Afferent Pharmaceuticals, Acceleron Pharma, ArQule, and Tilos Therapeutics.
Mr. Smart has also served as Senior Vice President-Finance & Global Controller at Merck & Co., Inc. since 2023 and is a Central Board Member at Junior Achievement of New Jersey, Inc. Mr. Smart is currently Chief Executive Officer at Harpoon Therapeutics, Inc., Calporta Therapeutics, Inc., Prometheus Biosciences, Inc., and Imago BioSciences, Inc.; President & Director at Caraway Therapeutics, Inc., Acceleron Pharma, Inc., and ArQule, Inc.; President, Director & Vice President-Tax at Tilos Therapeutics, Inc.; Chief Executive Officer & Director at Afferent Pharmaceuticals, Inc.; Senior Vice President-Finance & Global Controller at Merck & Co., Inc.; Central Board Member at Junior Achievement of New Jersey, Inc.; and Director at Terns Pharmaceuticals, Inc. starting in 2026.